Ritucad 500 mg Injection
  1. Home
  2. Pharma Products
  3. Cadila Pharmaceutical Ltd
  4. Ritucad 500 mg Injection

Ritucad 500 mg Injection

Ritucad 500 mg Injection contains rituximab, a monoclonal antibody used mainly to treat certain blood cancers and autoimmune disorders. It is supplied as a 500 mg/50 mL injection and is administered by intravenous infusion under medical supervision. Rituximab targets CD20-positive B cells and helps the immune system destroy abnormal B cells.

BUY NOW

Category

Ritucad 500 mg Injection is used in treatment protocols for conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukaemia, as well as selected autoimmune disorders. Rituximab binds to the CD20 protein on B cells, promoting their elimination through immune-mediated mechanisms. The medicine is given as a controlled intravenous infusion according to the prescribed treatment schedule. Patients should be monitored for infusion reactions, infections, blood-count changes, and other treatment-related effects.

Technical Specification

Specification Details
Active Ingredient Rituximab
Strength 500 mg
Concentration 10 mg/mL
Dosage Form Injection
Route of Administration Intravenous Infusion
Pack Size 1 Vial of 50 mL
Manufacturer Cadila Pharmaceuticals Ltd

Product Also Known As

Ritucad 500 mg Injection, Ritucad 500 Injection, Ritucad Rituximab Injection, Rituximab 500 mg Injection, Rituximab 500 mg/50 mL Injection, Rituximab Cancer Injection